Report topline efficacy data from the DUPLEX study
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 11 Jan 2021
- Due
- 28 Feb 2021
- Delivered
- February 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The Phase 3 DUPLEX Study of sparsentan in focal segmental glomerulosclerosis (FSGS) is on track to report topline efficacy data from the 36-week interim proteinuria endpoint analysis in February 2021.”
What we found
Evidence strength A What the grades mean
The company announced in February 2021 that the Phase 3 DUPLEX study had achieved its pre-specified interim efficacy endpoint, meeting the commitment to report topline data within that month.
-
A Travere Therapeutics, Inc. 10-K filed 2021-03-01
“In February 2021, we announced that our ongoing pivotal Phase 3 DUPLEX Study of sparsentan in focal segmental glomerulosclerosis (“FSGS”) achieved its pre-specified interim FSGS partial remission of proteinuria endpoint (“FPRE”)” ✓ confirmed on the page
Market reaction: the shares moved -11.4% against the S&P 500 over the three sessions around the disclosure (26 Feb 2021 to 3 Mar 2021). What this measures
Checked 24 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- DUPLEX study topline efficacy data
- Target
- 36 weeks
- Language
- Firm (“will”, “on track to”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Travere Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-TVTX-021542 · Corrections policy